AU Patent

AU2018390826B2 — Abuse deterrent morphine sulfate dosage forms

Assigned to Purdue Pharma LP · Expires 2024-09-12 · 2y expired

What this patent protects

The present invention relates to a solid oral extended release pharmaceutical dosage form comprising a cured extended release matrix formulation, the extended release matrix formulation comprising: a therapeutically effective amount of morphine sulfate, and polyethylene oxide. Th…

USPTO Abstract

The present invention relates to a solid oral extended release pharmaceutical dosage form comprising a cured extended release matrix formulation, the extended release matrix formulation comprising: a therapeutically effective amount of morphine sulfate, and polyethylene oxide. The invention further relates to a process of preparing the dosage form as well as to a method of treating pain by administering the dosage form

Drugs covered by this patent

Patent Metadata

Patent number
AU2018390826B2
Jurisdiction
AU
Classification
—
Expires
2024-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Purdue Pharma LP
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.